Phenotypic assays and sequencing are less sensitive than point mutation assays for detection of resistance in mixed HIV-1 genotypic populations
about
Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analoguesPrevalence and impact of minority variant drug resistance mutations in primary HIV-1 infectionDeep sequencing of HIV-1 near full-length proviral genomes identifies high rates of BF1 recombinants including two novel circulating recombinant forms (CRF) 70_BF1 and a disseminating 71_BF1 among blood donors in Pernambuco, BrazilEnhanced detection of viral diversity using partial and near full-length genomes of human immunodeficiency virus Type 1 provirus deep sequencing data from recently infected donors at four blood centers in Brazil.Frequency of Drug-Resistant Variants of HIV-1 Coexistent With Wild-Type in Treatment-Naive Patients of IndiaHigh-resolution quantification of hepatitis C virus genome-wide mutation load and its correlation with the outcome of peginterferon-alpha2a and ribavirin combination therapyGenotypic testing for human immunodeficiency virus type 1 drug resistance.Biomarker discovery using targeted maximum-likelihood estimation: application to the treatment of antiretroviral-resistant HIV infectionRapid identification of Mycobacteria to the species level using INNO-LiPA Mycobacteria, a reverse hybridization assay.Comparison between sequence analysis and a line probe assay for testing genotypic resistance of human immunodeficiency virus type 1 to antiretroviral drugs.Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assayMutagenically separated PCR assay for rapid detection of M41L and K70R zidovudine resistance mutations in CRF01_AE (subtype E) human immunodeficiency virus type 1.Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent.Rapid and sensitive oligonucleotide ligation assay for detection of mutations in human immunodeficiency virus type 1 associated with high-level resistance to protease inhibitors.Characterizing the emergence and persistence of drug resistant mutations in HIV-1 subtype C infections using 454 ultra deep pyrosequencingAnalysis of low-frequency mutations associated with drug resistance to raltegravir before antiretroviral treatment.Use of amplification refractory mutation system PCR assay as a simple and effective tool to detect HIV-1 drug resistance mutations.Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer IDA Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.Feasibility of detecting human immunodeficiency virus type 1 drug resistance in DNA extracted from whole blood or dried blood spots.Characterization of the Drug Resistance Profiles of Patients Infected with CRF07_BC Using Phenotypic Assay and Ultra-Deep Pyrosequencing.The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.Novel enzyme-linked minisequence assay for genotypic analysis of human immunodeficiency virus type 1 drug resistance.Comparison of oligonucleotide ligation assay and consensus sequencing for detection of drug-resistant mutants of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and plasma.Performance evaluation of the HepB Typer-Entecavir kit for detection of entecavir resistance mutations in chronic hepatitis B.Multimethod Longitudinal HIV Drug Resistance Analysis in Antiretroviral-Therapy-Naive Patients.Discordance between genotypic and phenotypic drug resistance profiles in human immunodeficiency virus type 1 strains isolated from peripheral blood mononuclear cells.Multiple viral genetic analyses detect low-level human immunodeficiency virus type 1 replication during effective highly active antiretroviral therapy.Differential maintenance of the M184V substitution in the reverse transcriptase of human immunodeficiency virus type 1 by various nucleoside antiretroviral agents in tissue culture.Sequencing-based detection of low-frequency human immunodeficiency virus type 1 drug-resistant mutants by an RNA/DNA heteroduplex generator-tracking assayEvidence for deleterious hepatitis C virus quasispecies mutation loads that differentiate the response patterns in IFN-based antiviral therapy.High prevalence of HIV-1 transmitted drug-resistance mutations from proviral DNA massively parallel sequencing data of therapy-naïve chronically infected Brazilian blood donors.Theoretical and experimental assessment of degenerate primer tagging in ultra-deep applications of next-generation sequencing.The HIV-1 transmission bottleneck.Evolution of primary and compensatory lamivudine resistance mutations in chronic hepatitis B virus-infected patients during long-term lamivudine treatment, assessed by a line probe assay.Frequency of drug-resistant variants of HIV-1 coexistent with wild-type in treatment-naive patients of India
P2860
Q28344476-6782AEB6-0ED0-45D0-A26C-6FA33705F3E3Q28478459-9339FE67-EABE-4EE0-8F94-F277071FC839Q28544988-CE49248E-089F-41CC-A623-D6C10419B3D7Q30870822-29E94D3B-2F10-4262-B1DF-C4FAE0F545A3Q33583299-B888267A-82D2-40C5-8C77-9620A6932A1FQ33784107-DCE4B6ED-6698-402B-BA9B-30DCCD67F1F4Q33906239-A8E070ED-5EBC-4AF4-8691-A8DF70CF7444Q33938373-A787F1AF-8379-4D0F-8749-C4970774A7CEQ33974339-5AAC4054-14CE-4247-8EE5-8DC27EB0993DQ34041782-6BBC29C1-473D-4E4B-B785-6F1487BCC968Q34200074-04A27E69-A803-4D0A-9C34-FB64DF84402BQ34252835-D9445C1D-E34C-4152-9EAE-DA8686C4DD3FQ34352000-EE4F6EC6-CFA5-44EC-B1FC-24262E569AD6Q34454630-BDB0518E-3AC0-4C51-8030-8719B7CBBA8DQ34567556-DA58797C-3A91-45B3-B3FC-28596875D059Q34737411-090763D4-21D1-4651-8BF0-6369AEEF5BD5Q35455456-EC088B84-695D-426E-A38B-A3AC5FD3257DQ35647691-6A26BE0E-A017-43E7-8CF4-FB97C22B38E1Q35742512-6F6A82B7-B146-4C80-A28C-A433C31C3406Q36098805-A010C025-85D7-4999-9F88-580A2DB1219CQ36255602-1E3435A4-8483-419F-84C8-ADF0F7CD8612Q37018369-3C68DAEF-CB14-4D58-A0DE-F78E0DB15FF8Q37058422-7C40FD6A-11F6-48AB-9323-2CB8F7566263Q37156918-81B4EF8E-E97E-4F11-A28D-BC479CB591ECQ37488838-5CEF3EEE-910A-4F20-BD4B-6280594F625BQ38703935-3CC86892-8E27-4DCC-A26B-3FAD46194F25Q39746816-C63FDFCC-6E11-414F-A90A-C54AA23C3CCEQ39748924-A9BC10CA-B391-45F5-8959-CB0B6A3E26D4Q40291316-CB215931-DF37-4DE2-85A4-80C9312F7E70Q40909665-CCDAA515-C9BD-4B10-8CDC-959D5A4ADCA2Q41115175-2BFC3D8C-5B68-46AD-8CA4-CA516BFB10F1Q41929325-3CC83C80-78ED-4E45-936D-BEDED830EED7Q42219806-4C85625D-EF5A-44B2-B7B9-8E1F43045DC6Q42314454-82D7E3BB-88CA-417A-9164-6DA2B12A2A91Q42910007-C381257A-6F20-46E0-865A-498FC5E33F63Q56965171-61E9AC3B-7506-4E23-A6AF-ACA0846F7C83
P2860
Phenotypic assays and sequencing are less sensitive than point mutation assays for detection of resistance in mixed HIV-1 genotypic populations
description
article
@en
im Oktober 1999 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в жовтні 1999
@uk
name
Phenotypic assays and sequenci ...... ed HIV-1 genotypic populations
@en
Phenotypic assays and sequenci ...... ed HIV-1 genotypic populations
@nl
type
label
Phenotypic assays and sequenci ...... ed HIV-1 genotypic populations
@en
Phenotypic assays and sequenci ...... ed HIV-1 genotypic populations
@nl
prefLabel
Phenotypic assays and sequenci ...... ed HIV-1 genotypic populations
@en
Phenotypic assays and sequenci ...... ed HIV-1 genotypic populations
@nl
P2093
P1476
Phenotypic assays and sequenci ...... ed HIV-1 genotypic populations
@en
P2093
A M Vandamme
E De Clercq
E Van Wijngaerden
J C Schmit
J Desmyter
K Van Laethem
K Van Vaerenbergh
M Van Ranst
M Witvrouw
P304
P407
P577
1999-10-01T00:00:00Z